Amneal reported Q4 FY2025 net revenue of USD 814 million (+11.0%), GAAP net income attributable to shareholders of USD 35 million and diluted EPS of USD 0.11. Q4 adjusted net income was USD 68 million, adjusted EBITDA was USD 175 million (+13.0%), and adjusted diluted EPS was USD 0.21. For FY2025, Amneal posted net revenue of USD 3.02 billion (+8.0%), GAAP net income attributable to shareholders of USD 72 million and diluted EPS of USD 0.22. FY adjusted net income was USD 269 million, adjusted EBITDA was USD 688 million (+10.0%), adjusted diluted EPS was USD 0.83, and operating cash flow was USD 340 million (capital expenditures: USD 89 million). Business highlights included Specialty net revenue growth of 38.0% in Q4 driven by Crexont and Unithroid, while Affordable Medicines net revenue decreased 1.0% due to timing of revenue for key products and new launches; AvKARE net revenue rose 24.0% driven by government label sales. The company cited continued uptake of Crexont, the launch of the Brekiya autoinjector, and new product approvals including its first two inhalation products and its fourth and fifth biosimilars. Amneal also issued FY2026 guidance for net revenue of USD 3.05 billion to USD 3.15 billion, adjusted EBITDA of USD 720 million to USD 760 million, and adjusted diluted EPS of USD 0.93 to USD 1.03.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602270600PRIMZONEFULLFEED9662651) on February 27, 2026, and is solely responsible for the information contained therein.
Comments